Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P01130: Variant p.Asp266Glu

Low-density lipoprotein receptor
Gene: LDLR
Feedback?
Variant information Variant position: help 266 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Aspartate (D) to Glutamate (E) at position 266 (D266E, p.Asp266Glu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and acidic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In FHCL1; pathogenic; Cincinnati-1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 266 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 860 The length of the canonical sequence.
Location on the sequence: help GNCIHGSRQCDREYDCKDMS D EVGCVNVTLCEGPNKFKCHS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         GNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHS

Mouse                         GSCIHGSRQCDREHDCKDMSDELGCVNVTQCDGPNKFKCHS

Rat                           GSCIHGSRQCDREHDCKDMSDELGCINVTQCDGPNKFKCHS

Bovine                        GTCIHGSRQCDREPDCKDLSDELGCVNVTLCEGPNKFKCQS

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 22 – 860 Low-density lipoprotein receptor
Topological domain 22 – 788 Extracellular
Domain 234 – 272 LDL-receptor class A 6
Glycosylation 272 – 272 N-linked (GlcNAc...) asparagine
Disulfide bond 255 – 270
Alternative sequence 105 – 272 Missing. In isoform 3.
Alternative sequence 273 – 273 V -> L. In isoform 3.
Helix 265 – 267



Literature citations
Molecular genetics of the LDL receptor gene in familial hypercholesterolemia.
Hobbs H.H.; Brown M.S.; Goldstein J.L.;
Hum. Mutat. 1:445-466(1992)
Cited for: VARIANTS FHCL1 TYR-52; ARG-109; GLY-155; ARG-173; PHE-197; TYR-197; ASN-224; GLY-224; PRO-226; LYS-240; PHE-248; GLY-256; GLU-266; TYR-270; ARG-286; ASN-304; GLU-304; TYR-318; SER-335; GLU-342; SER-343; TYR-352; VAL-354; GLY-354; LYS-357; ARG-364; ARG-379; ASN-441; MET-441; CYS-443; ARG-478; ARG-485; VAL-565; SER-599; PRO-682; PHE-792 AND ILE-827; Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations.
Widhalm K.; Dirisamer A.; Lindemayr A.; Kostner G.;
J. Inherit. Metab. Dis. 30:239-247(2007)
Cited for: VARIANTS FHCL1 THR-50; LEU-211; GLY-221; GLU-266; LYS-277; ARG-286; ARG-314; ARG-352; LYS-408; THR-431; HIS-442; MET-523; GLY-577; THR-585 AND LEU-685;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.